No insider purchase over the last 90 days. The latest, by Li Jincai, was filed 13 Apr 2026.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate WuXi XDC Cayman Inc. Strong Buy (bullish), based on 20 analysts. Average price target: HK$92.65.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 43 declarations
WuXi XDC, a healthcare group listed in Hong Kong (HKD 95.7 billion market capitalisation, 64.6% of the capital held by insiders), has a small record of 43 filings, the first published on November 22, 2023 and the latest on September 2, 2026, from 5 filers. There are 10 purchases, only one with an amount: EUR 1,119,370 for director Chen Zhisheng, on November 17, 2023. The 9 sales total EUR 7.6 million, median EUR 166,719, so 53% purchases.
Director Zhang Jerry Jingwei provides the three largest sales: EUR 2.9 million on August 28, 2026, EUR 1.7 million on July 6, 2026 and EUR 1.6 million on September 9, 2025. That filer has 15 filings, 3 purchases and 6 sales. Xi Xiaojie and Li Jincai have 11 filings each, with 3 purchases and 1 sale. Shi Ming has 3, one of them a sale.
On April 8, 2026, 3 insiders filed on the same day. The record also holds 24 other filings. Yearly volume is 9 in 2023, 3 in 2024, 7 in 2025 and 24 in 2026. In the last twelve months: 26 filings, 3 purchases, 7 sales. The publication delay is a median of 4 days.